Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, …
Over the last 12 months, insiders at Treace Medical Concepts, Inc. have bought $7.31M and sold $0 worth of Treace Medical Concepts, Inc. stock.
On average, over the past 5 years, insiders at Treace Medical Concepts, Inc. have bought $2.33M and sold $106.84M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Treace John T. (Chief Executive Officer) — $3.73M. TREACE JAMES T (director) — $2.07M. BAKEWELL JOHN K (director) — $1.19M.
The last purchase of 50,000 shares for transaction amount of $265,630 was made by Treace John T. (Chief Executive Officer) on 2024‑09‑16.
2024-09-16 | Chief Executive Officer | 50,000 0.0853% | $5.31 | $265,630 | +5.59% | |||
2024-08-15 | director | 84,000 0.1435% | $5.96 | $501,035 | 0.00% | |||
2024-08-14 | Chief Executive Officer | 85,000 0.1461% | $6.00 | $510,315 | 0.00% | |||
2024-06-11 | Chief Executive Officer | 45,000 0.0729% | $5.88 | $264,600 | -1.20% | |||
2024-05-31 | director | 25,000 0.0415% | $6.05 | $151,328 | -1.53% | |||
2024-05-29 | director | 25,000 0.0397% | $5.20 | $130,063 | +9.66% | |||
2024-05-28 | director | 50,000 0.0809% | $5.07 | $253,475 | +14.46% | |||
2024-05-24 | director | 18,000 0.0299% | $5.19 | $93,501 | +11.82% | |||
2024-05-22 | director | 12,100 0.0183% | $4.99 | $60,425 | +7.88% | |||
2024-05-17 | Chief Executive Officer | 100,000 0.156% | $5.56 | $556,170 | +14.70% | |||
2024-05-14 | Chief Executive Officer | 150,000 0.2476% | $5.12 | $767,805 | +15.09% | |||
2024-05-14 | director | 19,356 0.0323% | $5.17 | $100,001 | +15.09% | |||
2024-05-13 | Chief Executive Officer | 150,000 0.2433% | $4.56 | $683,490 | +25.77% | |||
2024-05-13 | director | 145,000 0.2342% | $4.54 | $657,981 | +25.77% | |||
2024-05-13 | director | 36,802 0.0573% | $4.38 | $161,090 | +25.77% | |||
2024-05-10 | Chief Executive Officer | 150,000 0.2529% | $4.58 | $686,880 | +30.14% | |||
2024-05-10 | director | 83,198 0.1399% | $4.57 | $379,849 | +30.14% | |||
2024-05-10 | director | 83,000 0.1384% | $4.53 | $376,023 | +30.14% | |||
2024-05-10 | director | 130,000 0.2189% | $4.57 | $594,620 | +30.14% | |||
2024-05-10 | director | 25,000 0.0414% | $4.50 | $112,568 | +30.14% |
Treace John T. | Chief Executive Officer | 6523095 10.4889% | $7.85 | 12 | 15 | +15.13% |
TREACE JAMES T | director | 1223441 1.9673% | $7.85 | 6 | 32 | |
MOTT RICHARD W | director | 1072944 1.7253% | $7.85 | 4 | 19 | |
BAKEWELL JOHN K | director | 135048 0.2172% | $7.85 | 1 | 0 | |
Jain Deepti | director | 31235 0.0502% | $7.85 | 1 | 0 |
The Vanguard Group | $56.16M | 6.94 | 4.3M | +0.22% | +$125,410.50 | <0.01 | |
BlackRock | $48.29M | 5.97 | 3.7M | +0.23% | +$108,249.75 | <0.01 | |
Morgan Stanley | $42.96M | 5.31 | 3.29M | +5.59% | +$2.28M | <0.01 | |
Armistice Capital Llc | $31.32M | 3.87 | 2.4M | -15.97% | -$5.95M | 0.1 | |
William Blair Investment Management | $30.4M | 3.76 | 2.33M | -18.78% | -$7.03M | 0.08 |